# 4<sup>th</sup> International Symposium on Hodgkin Lymphoma

## 10th Prague Hematology Days

## **PROGRAMME**

#### October 11, 2012

#### Is pathology still relevant today?

H.Stein, Berlin, Germany

#### New drugs in the treatment of Hodgkin lymphoma

A. Younes, Houston, USA

#### MicroRNA in Hodgkin lymphoma

T.Stopka, Prague, Czech Republic

#### Recent and current EORTC Lymphoma Group trials

J.M.Raemaekers, Nijmegen, The Netherlands

#### **GHSG** trials

M.Fuchs, Cologne, Germany

#### **UK NCRI trials in Hodgkin lymphoma**

J.Radford, Manchester, United Kingdom

#### PET guided therapy in GHSG trials

C.Kobe, Cologne, Germany

#### PET during follow-up and before autologous stem cell transplantation in Hodgkin lymphoma

H.Mociková, Prague, Czech Republic

#### The role of radiotherapy in current GHSG protocols

J.Kriz, Münster, Germany

#### New modalities of radiotherapy in lymphomas

K.Dědečková, Prague, Czech Republic

### EuroNet-PHL-C1 interim results and concept for EuroNet-PHL-C2 trial

C.Mauz-Körholz, Halle, Germany

#### **EuroNet-PHL-C1 study in Czech Republic**

M.Čepelová, Prague, Czech Republic

#### **Poster presentations**

# 4<sup>th</sup> International Symposium on Hodgkin Lymphoma

# 10th Prague Hematology Days

## **PROGRAMME**

#### October 12, 2012

**Autologous and allogeneic stem cell transplantation in Hodgkin lymphoma, the role of DLI** *A.Sureda, Barcelona, Spain* 

Allogeneic stem cell transplantation in Hodgkin lymphoma in Czech Republic V. Válková, Prague, Czech Republic

Treatment of relapsed Hodgkin lymphoma B. von Tresckow, Cologne, Germany

Nodular lymphocyte predominant Hodgkin lymphoma - treatment and outcome *H.Mociková, Prague, Czech Republic* 

**Treatment of elderly Hodgkin lymphoma patients within GHSG trials** *B.Böll, Cologne, Germany* 

**Gonadal function in patients treated within the GHSG HD13 - 15 trials** *K.Behringer, Cologne, Germany* 

Tretment of Hodgkin lymphoma in pregnancy L.Šmardová, Brno, Czech Republic

 ${\bf Selected\ abstracts\ for\ oral\ presentations}$ 

Hematologists ≤ 35 years are strongly encouraged